New drug aims to reduce deaths from severe lung failure
Disease control
Recruiting now
This study tests an experimental drug called recombinant human plasma gelsolin (rhu-pGSN) added to standard care for people with moderate-to-severe acute respiratory distress syndrome (ARDS) caused by pneumonia or other infections. About 600 hospitalized adults will receive eithe…
Phase: PHASE2 • Sponsor: BioAegis Therapeutics Inc. • Aim: Disease control
Last updated Jun 01, 2026 17:53 UTC